vorinostat has been researched along with Hypertrophy in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "One of the earliest features of diabetic nephropathy is renal enlargement." | 1.37 | Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. ( Advani, A; Advani, SL; Connelly, KA; Gilbert, RE; Huang, Q; Lee, K; Thai, K; Yuen, DA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gilbert, RE | 1 |
| Huang, Q | 1 |
| Thai, K | 1 |
| Advani, SL | 1 |
| Lee, K | 1 |
| Yuen, DA | 1 |
| Connelly, KA | 1 |
| Advani, A | 1 |
1 other study available for vorinostat and Hypertrophy
| Article | Year |
|---|---|
Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor.
Topics: Analysis of Variance; Animals; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; | 2011 |